AU2007261530B2 - Serum-free media and their uses for chondrocyte expansion - Google Patents
Serum-free media and their uses for chondrocyte expansion Download PDFInfo
- Publication number
- AU2007261530B2 AU2007261530B2 AU2007261530A AU2007261530A AU2007261530B2 AU 2007261530 B2 AU2007261530 B2 AU 2007261530B2 AU 2007261530 A AU2007261530 A AU 2007261530A AU 2007261530 A AU2007261530 A AU 2007261530A AU 2007261530 B2 AU2007261530 B2 AU 2007261530B2
- Authority
- AU
- Australia
- Prior art keywords
- chondrocytes
- acid
- osm
- cells
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000001612 chondrocyte Anatomy 0.000 title claims abstract description 127
- 239000004017 serum-free culture medium Substances 0.000 title abstract description 16
- 108090000630 Oncostatin M Proteins 0.000 claims abstract description 103
- 102000004140 Oncostatin M Human genes 0.000 claims abstract description 103
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 101
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 101
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 79
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims abstract description 66
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims abstract description 66
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims abstract description 48
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims abstract description 48
- 150000002632 lipids Chemical class 0.000 claims abstract description 38
- 210000002966 serum Anatomy 0.000 claims abstract description 33
- 210000004027 cell Anatomy 0.000 claims description 234
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 79
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 68
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 46
- 235000012000 cholesterol Nutrition 0.000 claims description 42
- 229940107161 cholesterol Drugs 0.000 claims description 42
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 39
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 39
- 229960004488 linolenic acid Drugs 0.000 claims description 39
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 39
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 39
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 37
- 239000007640 basal medium Substances 0.000 claims description 37
- 241000282414 Homo sapiens Species 0.000 claims description 35
- 235000021355 Stearic acid Nutrition 0.000 claims description 34
- 229940114079 arachidonic acid Drugs 0.000 claims description 34
- 235000021342 arachidonic acid Nutrition 0.000 claims description 34
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 34
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 34
- 239000008117 stearic acid Substances 0.000 claims description 34
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 27
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 27
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 26
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 26
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 26
- 239000005642 Oleic acid Substances 0.000 claims description 26
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 26
- 239000001963 growth medium Substances 0.000 claims description 26
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 26
- 235000021313 oleic acid Nutrition 0.000 claims description 26
- 210000000845 cartilage Anatomy 0.000 claims description 25
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 25
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 23
- 235000021314 Palmitic acid Nutrition 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 23
- 229940042585 tocopherol acetate Drugs 0.000 claims description 23
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 22
- 102000004142 Trypsin Human genes 0.000 claims description 21
- 108090000631 Trypsin Proteins 0.000 claims description 21
- 239000012588 trypsin Substances 0.000 claims description 21
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 19
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 19
- 230000007547 defect Effects 0.000 claims description 15
- 102000003816 Interleukin-13 Human genes 0.000 claims description 11
- 108090000176 Interleukin-13 Proteins 0.000 claims description 11
- 230000001902 propagating effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 6
- XUGISPSHIFXEHZ-UHFFFAOYSA-N 3beta-acetoxy-cholest-5-ene Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XUGISPSHIFXEHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 abstract description 7
- 238000012258 culturing Methods 0.000 abstract description 4
- 230000002062 proliferating effect Effects 0.000 abstract description 4
- 239000006143 cell culture medium Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012136 culture method Methods 0.000 abstract 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 67
- 239000002609 medium Substances 0.000 description 64
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 61
- 239000012091 fetal bovine serum Substances 0.000 description 60
- 230000012010 growth Effects 0.000 description 35
- 239000013589 supplement Substances 0.000 description 28
- 210000001188 articular cartilage Anatomy 0.000 description 23
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 238000004113 cell culture Methods 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 15
- 238000001574 biopsy Methods 0.000 description 13
- 239000012679 serum free medium Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 235000020778 linoleic acid Nutrition 0.000 description 12
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 12
- 102000029816 Collagenase Human genes 0.000 description 11
- 108060005980 Collagenase Proteins 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 229960002424 collagenase Drugs 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 230000006862 enzymatic digestion Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 239000004365 Protease Substances 0.000 description 10
- 241000187392 Streptomyces griseus Species 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 229940072056 alginate Drugs 0.000 description 9
- 235000010443 alginic acid Nutrition 0.000 description 9
- 229920000615 alginic acid Polymers 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- 102000016284 Aggrecans Human genes 0.000 description 8
- 108010067219 Aggrecans Proteins 0.000 description 8
- 102000016611 Proteoglycans Human genes 0.000 description 8
- 108010067787 Proteoglycans Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229960004274 stearic acid Drugs 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 102000043136 MAP kinase family Human genes 0.000 description 6
- 108091054455 MAP kinase family Proteins 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 5
- 108010081589 Becaplermin Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 5
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 5
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 5
- 235000021360 Myristic acid Nutrition 0.000 description 5
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 102100029391 Cardiotrophin-like cytokine factor 1 Human genes 0.000 description 3
- 101710107109 Cardiotrophin-like cytokine factor 1 Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 3
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 3
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 3
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 3
- 102000015617 Janus Kinases Human genes 0.000 description 3
- 108010024121 Janus Kinases Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 102000046645 human LIF Human genes 0.000 description 3
- -1 lL-6 Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 229940023607 myristic acid Drugs 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102100037597 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000992170 Homo sapiens Oncostatin-M Proteins 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 108010041776 cardiotrophin 1 Proteins 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 102000052611 human IL6 Human genes 0.000 description 2
- 102000043703 human OSM Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- SDTYLAIVXLZQGT-UHFFFAOYSA-N 14-oxoicosanoic acid Chemical compound O=C(CCCCCCCCCCCCC(=O)O)CCCCCC SDTYLAIVXLZQGT-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010061762 Chondropathy Diseases 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 108700003486 Jagged-1 Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710111489 Neurotrophin 1 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100032702 Protein jagged-1 Human genes 0.000 description 1
- 108700037966 Protein jagged-1 Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000002164 acetylcholinergic effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001162 elastic cartilage Anatomy 0.000 description 1
- 229950003349 emfilermin Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 210000000968 fibrocartilage Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/237—Oncostatin M [OSM]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014202438A AU2014202438A1 (en) | 2006-06-20 | 2014-05-05 | Serum-Free Media and Their Uses for Chondrocyte Expansion |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80530706P | 2006-06-20 | 2006-06-20 | |
| US60/805,307 | 2006-06-20 | ||
| PCT/US2007/014075 WO2007149328A1 (en) | 2006-06-20 | 2007-06-15 | Serum-free media and their uses for chondrocyte expansion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014202438A Division AU2014202438A1 (en) | 2006-06-20 | 2014-05-05 | Serum-Free Media and Their Uses for Chondrocyte Expansion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007261530A1 AU2007261530A1 (en) | 2007-12-27 |
| AU2007261530B2 true AU2007261530B2 (en) | 2014-02-06 |
Family
ID=38626563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007261530A Ceased AU2007261530B2 (en) | 2006-06-20 | 2007-06-15 | Serum-free media and their uses for chondrocyte expansion |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20070292949A1 (https=) |
| EP (1) | EP2032689A1 (https=) |
| JP (1) | JP2009540826A (https=) |
| CN (1) | CN101490245B (https=) |
| AU (1) | AU2007261530B2 (https=) |
| BR (1) | BRPI0713572A2 (https=) |
| IL (1) | IL196025A (https=) |
| MX (1) | MX2008016429A (https=) |
| WO (1) | WO2007149328A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| SI2132562T1 (sl) | 2007-04-06 | 2012-05-31 | Genzyme Corp | Metode za ovrednotenje celic in celičnih kultur |
| CN102411484B (zh) * | 2010-09-20 | 2015-01-28 | 联想(北京)有限公司 | 一种显示系统中的图像显示方法和装置 |
| KR101138091B1 (ko) * | 2011-08-31 | 2012-04-24 | 세원셀론텍(주) | 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제 |
| LT2753346T (lt) | 2011-09-07 | 2020-08-10 | Mount Sinai School Of Medicine | Ceramidazė ir ląstelių diferenciacija |
| ES2897825T3 (es) | 2012-06-01 | 2022-03-02 | Icahn School Med Mount Sinai | Niveles de ceramida en el tratamiento y prevención de infecciones |
| US9664671B2 (en) | 2012-07-24 | 2017-05-30 | Nissan Chemical Industries, Ltd. | Culture medium composition and method of culturing cell or tissue using thereof |
| US10017805B2 (en) | 2012-08-23 | 2018-07-10 | Nissan Chemical Industries, Ltd. | Enhancing ingredients for protein production from various cells |
| CN104781389B (zh) * | 2012-08-23 | 2018-05-29 | 日产化学工业株式会社 | 蛋白质生产促进剂 |
| US8835175B2 (en) * | 2012-11-13 | 2014-09-16 | Grifols, S.A. | Culture medium for human mesenchymal stem cells |
| EP2733200A1 (en) | 2012-11-15 | 2014-05-21 | Biorigen International SA | Cell culture supplements |
| PT2968479T (pt) | 2013-03-14 | 2019-08-07 | Icahn School Med Mount Sinai | Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização |
| WO2015016357A1 (ja) * | 2013-08-01 | 2015-02-05 | 株式会社ツーセル | 軟骨損傷治療剤及びその製造方法 |
| CN104630138B (zh) * | 2013-11-06 | 2017-11-14 | 陕西瑞盛生物科技有限公司 | 一种无血清软骨细胞培养液 |
| JP2016067312A (ja) * | 2014-09-30 | 2016-05-09 | 株式会社ジーシー | 軟骨分化培養液、及び軟骨組織 |
| WO2016076102A1 (ja) * | 2014-11-14 | 2016-05-19 | 株式会社リジェネシスサイエンス | 軟骨細胞の無血清培養方法，及び無血清培地 |
| CN107849529A (zh) * | 2014-12-31 | 2018-03-27 | 迈克尔·莫勒 | 用于人脂肪基质细胞临床生长的细胞培养基的人血清 |
| CN108295243A (zh) * | 2018-02-27 | 2018-07-20 | 上海中医药大学附属龙华医院 | 可溶性Jagged1肽在制备促进关节软骨修复的药物中的应用 |
| CN109022356A (zh) * | 2018-08-30 | 2018-12-18 | 丰泽康生物医药（深圳）有限公司 | 一种提高间充质干细胞向软骨细胞分化的无血清培养基 |
| PH12021552425A1 (en) * | 2019-03-29 | 2022-07-11 | Kolon Tissuegene Inc | Mixed-cell gene therapy |
| CN111019887A (zh) * | 2019-11-11 | 2020-04-17 | 浙江卫未生物医药科技有限公司 | 阻止软骨细胞去分化的培育方法 |
| CN113215085B (zh) * | 2021-05-07 | 2024-05-10 | 澳门大学 | 一种脂类物质添加剂及其应用 |
| CN113106066B (zh) * | 2021-05-13 | 2022-08-23 | 杭州艾名医学科技有限公司 | 一种肉瘤细胞培养基以及采用该培养基体外生产Matrigel原液的方法 |
| US11692167B2 (en) | 2021-08-02 | 2023-07-04 | Montana State University | Chemically defined serum replacements for cell culture |
| WO2025117331A1 (en) | 2023-12-01 | 2025-06-05 | Eli Lilly And Company | Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same |
| CN118909927B (zh) * | 2024-09-12 | 2025-09-12 | 上海多宁生物科技股份有限公司 | 一种高表达的cho细胞培养方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT87133B (pt) * | 1987-04-02 | 1992-07-31 | Amrad Corp Ltd | Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif |
| US5202116A (en) * | 1989-04-10 | 1993-04-13 | Oncogen | Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m |
| US5814307A (en) * | 1989-04-10 | 1998-09-29 | Bristol-Myers Squibb Company | Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6 |
| US5843892A (en) * | 1989-12-18 | 1998-12-01 | California Institute Of Technology | Stimulation of nerve growth and/or vitality |
| US5188828A (en) * | 1990-11-08 | 1993-02-23 | Brigham And Women's Hospital | Interleukin-6 to stimulate erythropoietin production |
| AU2882992A (en) * | 1991-11-06 | 1993-06-07 | Arthur A. Axelrad | Cell culture medium |
| US5908782A (en) * | 1995-06-05 | 1999-06-01 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
| EP0891419A4 (en) * | 1996-03-12 | 2000-03-01 | Life Technologies Inc | NUTRIENT ADDITIVE FOR HEMATOPOETIC CELL CULTURES |
| WO1998004681A2 (en) * | 1996-07-25 | 1998-02-05 | Genzyme Corporation | Chondrocyte media formulations and culture procedures |
| US5945337A (en) * | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
| US6156729A (en) * | 1997-10-15 | 2000-12-05 | California Institute Of Technology | Leukemia inhibitory factor for use in modulating inflammation and pain |
| JP2000319250A (ja) * | 1998-04-03 | 2000-11-21 | Sankyo Co Ltd | スルホンアミド誘導体 |
| CA2348687A1 (en) * | 1998-11-09 | 2000-05-18 | Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate | Serum free medium for chondrocyte-like cells |
| US20030202977A1 (en) * | 1998-11-16 | 2003-10-30 | New York University | Treatment of osteoarthritis |
| JP2001089390A (ja) * | 1999-09-16 | 2001-04-03 | Sumitomo Pharmaceut Co Ltd | 軟骨障害治療剤の新規なスクリーニング方法 |
| JP2001163885A (ja) * | 1999-09-29 | 2001-06-19 | Sankyo Co Ltd | スルホンアミド誘導体 |
| US6635802B1 (en) * | 2000-01-10 | 2003-10-21 | The Texas A&M University System | Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors |
| US7005252B1 (en) * | 2000-03-09 | 2006-02-28 | Wisconsin Alumni Research Foundation | Serum free cultivation of primate embryonic stem cells |
| EP1326980B1 (en) * | 2000-10-16 | 2008-03-19 | Genentech, Inc. | Methods of treatment using wisp polypeptides |
| PT1364023E (pt) * | 2000-12-08 | 2006-10-31 | Genentech Inc | Gene altamente expresso em tecidos de cartilagem |
| JP2002284686A (ja) * | 2001-03-28 | 2002-10-03 | Sankyo Co Ltd | スルホンアミド化合物を含有する医薬組成物 |
| EP1478734A4 (en) * | 2002-01-25 | 2006-04-05 | Genzyme Corp | NON-SERUM MEDIUM FOR CHONDROCYTES AND METHODS OF USE THEREOF |
| AU2003222043A1 (en) * | 2002-03-18 | 2003-10-08 | National Jewish Medical And Research Center | Method for production of neutrophils and uses therefor |
| JP2006522453A (ja) * | 2003-03-31 | 2006-09-28 | リットン・システムズ・インコーポレイテッド | マイクロチャネルプレートの接合方法 |
| DK1656130T3 (da) * | 2003-08-11 | 2008-11-24 | Hills Pet Nutrition Inc | Omega-3-fedtsyrer til behandling af osteoarthritis hos hunde |
| JP2007536936A (ja) * | 2004-05-14 | 2007-12-20 | ベクトン・ディキンソン・アンド・カンパニー | 幹細胞集団および使用方法 |
| US7615374B2 (en) * | 2007-09-25 | 2009-11-10 | Wisconsin Alumni Research Foundation | Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions |
-
2007
- 2007-06-15 US US11/763,587 patent/US20070292949A1/en not_active Abandoned
- 2007-06-15 AU AU2007261530A patent/AU2007261530B2/en not_active Ceased
- 2007-06-15 BR BRPI0713572-6A patent/BRPI0713572A2/pt not_active IP Right Cessation
- 2007-06-15 JP JP2009516524A patent/JP2009540826A/ja active Pending
- 2007-06-15 CN CN2007800274495A patent/CN101490245B/zh active Active
- 2007-06-15 EP EP07809587A patent/EP2032689A1/en not_active Withdrawn
- 2007-06-15 WO PCT/US2007/014075 patent/WO2007149328A1/en not_active Ceased
- 2007-06-15 MX MX2008016429A patent/MX2008016429A/es active IP Right Grant
-
2008
- 2008-12-18 IL IL196025A patent/IL196025A/en not_active IP Right Cessation
-
2012
- 2012-02-21 US US13/401,037 patent/US20120213745A1/en not_active Abandoned
-
2013
- 2013-04-16 US US13/864,149 patent/US20130273010A1/en not_active Abandoned
Non-Patent Citations (3)
| Title |
|---|
| BARKSBY, H.E. et al., Arthritis and Rheumatism, 2006, vol. 54, no. 2, pages 540-550 * |
| GROVE, R. I. et al., Proceedings of the National Academy of Sciences of the United States of America, 1993, Vol. 90, Pages 823-827. * |
| RADKA, S. F. et al., The Journal of Immunology, 1993, Vol. 150, No. 11, Pages 5195-5201 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2032689A1 (en) | 2009-03-11 |
| US20130273010A1 (en) | 2013-10-17 |
| MX2008016429A (es) | 2009-03-20 |
| CN101490245A (zh) | 2009-07-22 |
| AU2007261530A1 (en) | 2007-12-27 |
| IL196025A0 (en) | 2011-08-01 |
| WO2007149328A1 (en) | 2007-12-27 |
| CN101490245B (zh) | 2013-01-16 |
| JP2009540826A (ja) | 2009-11-26 |
| IL196025A (en) | 2014-12-31 |
| BRPI0713572A2 (pt) | 2012-10-23 |
| US20120213745A1 (en) | 2012-08-23 |
| US20070292949A1 (en) | 2007-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007261530B2 (en) | Serum-free media and their uses for chondrocyte expansion | |
| US7169610B2 (en) | Serum-free media for chondrocytes and methods of use thereof | |
| EP1988159B1 (en) | Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit | |
| US7932084B2 (en) | Methods and compositions for growing adipose stem cells | |
| EP0805853B1 (en) | Lineage-directed induction of human mesenchymal stem cell differentiation | |
| WO1996023059A9 (en) | Lineage-directed induction of human mesenchymal stem cell differentiation | |
| WO2021254296A1 (zh) | 一种生物活性物质组合物、包含所述组合物的无血清培养基及其用途 | |
| KR101920128B1 (ko) | 성장 인자 조합을 사용하는 골수 줄기 세포 및 간엽 줄기 세포의 골발생 분화 | |
| Rosselot et al. | Development of a serum-free system to study the effect of growth hormone and insulinlike growth factor-I on cultured postembryonic growth plate chondrocytes | |
| KR20110097064A (ko) | 무혈청 줄기 세포 배양 조성물, 이를 함유한 조직 재생용 조성물 및 이를 이용한 조직 재생 방법 | |
| US20080187518A1 (en) | Production of Osteoclasts from Adipose Tissues | |
| AU2014202438A1 (en) | Serum-Free Media and Their Uses for Chondrocyte Expansion | |
| KR102218126B1 (ko) | 소변 유래 줄기세포의 미분화능을 유지하는 방법 | |
| AU2003205290A1 (en) | Serum-free media for chondrocytes and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |